Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
16.19
USD
|
+0.81%
|
|
+3.19%
|
-9.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,511
|
1,697
|
1,399
|
981.9
|
789.7
|
794
|
-
|
-
|
Enterprise Value (EV)
1 |
1,215
|
1,221
|
941.1
|
617.3
|
514.4
|
643
|
619.4
|
756.1
|
P/E ratio
|
-15.9
x
|
-15.2
x
|
11.2
x
|
-3.49
x
|
-2.98
x
|
-3.93
x
|
-6.81
x
|
-9.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
42.9
x
|
11
x
|
2.97
x
|
8.71
x
|
8.75
x
|
5.91
x
|
3.64
x
|
2.9
x
|
EV / Revenue
|
34.5
x
|
7.9
x
|
2
x
|
5.48
x
|
5.7
x
|
4.79
x
|
2.84
x
|
2.76
x
|
EV / EBITDA
|
-8.56
x
|
-11
x
|
5.55
x
|
-2.47
x
|
-2.05
x
|
-5.34
x
|
25.4
x
|
17.8
x
|
EV / FCF
|
-10.2
x
|
-15.1
x
|
-
|
-2.59
x
|
-2.25
x
|
-4.23
x
|
-25.4
x
|
-687
x
|
FCF Yield
|
-9.83%
|
-6.63%
|
-
|
-38.6%
|
-44.4%
|
-23.7%
|
-3.94%
|
-0.15%
|
Price to Book
|
3.37
x
|
4.5
x
|
1.83
x
|
1.9
x
|
2.54
x
|
2.33
x
|
2.24
x
|
2.1
x
|
Nbr of stocks (in thousands)
|
36,874
|
37,408
|
42,769
|
43,294
|
43,992
|
49,043
|
-
|
-
|
Reference price
2 |
40.97
|
45.36
|
32.70
|
22.68
|
17.95
|
16.19
|
16.19
|
16.19
|
Announcement Date
|
2/26/20
|
3/1/21
|
3/1/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
35.23
|
154.6
|
470.3
|
112.7
|
90.24
|
134.4
|
218.4
|
273.7
|
EBITDA
1 |
-141.8
|
-110.8
|
169.5
|
-250
|
-250.8
|
-120.3
|
24.43
|
42.53
|
EBIT
1 |
-149
|
-119.2
|
160
|
-262.9
|
-268.1
|
-234
|
-154.3
|
-148.6
|
Operating Margin
|
-422.89%
|
-77.14%
|
34.01%
|
-233.2%
|
-297.12%
|
-174.18%
|
-70.67%
|
-54.28%
|
Earnings before Tax (EBT)
1 |
-97.49
|
-106
|
141.2
|
-280.4
|
-263.6
|
-208.1
|
-139.7
|
-107.5
|
Net income
1 |
-94.73
|
-111.2
|
127.8
|
-280.3
|
-263.5
|
-210.6
|
-134.3
|
-102.5
|
Net margin
|
-268.88%
|
-71.98%
|
27.18%
|
-248.68%
|
-291.99%
|
-156.77%
|
-61.47%
|
-37.45%
|
EPS
2 |
-2.580
|
-2.980
|
2.910
|
-6.500
|
-6.020
|
-4.119
|
-2.376
|
-1.777
|
Free Cash Flow
1 |
-119.4
|
-80.93
|
-
|
-238.2
|
-228.4
|
-152.1
|
-24.4
|
-1.1
|
FCF margin
|
-338.96%
|
-52.36%
|
-
|
-211.32%
|
-253.06%
|
-113.21%
|
-11.17%
|
-0.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
3/1/21
|
3/1/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
30.77
|
398.7
|
22.22
|
32.65
|
26.51
|
31.34
|
19.14
|
19.98
|
28.91
|
22.21
|
23.52
|
25.19
|
26.84
|
42.67
|
21.39
|
EBITDA
|
-54.52
|
316.2
|
-68.94
|
-59.89
|
-67.5
|
-53.64
|
-61.98
|
-68.67
|
-60.59
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-57.35
|
313.6
|
-71.53
|
-62.53
|
-71.04
|
-57.77
|
-66.16
|
-73.11
|
-64.96
|
-63.9
|
-60.37
|
-60.01
|
-59.09
|
-57.26
|
-55.5
|
Operating Margin
|
-186.36%
|
78.66%
|
-321.93%
|
-191.53%
|
-267.97%
|
-184.31%
|
-345.68%
|
-365.96%
|
-224.67%
|
-287.68%
|
-256.64%
|
-238.22%
|
-220.16%
|
-134.2%
|
-259.51%
|
Earnings before Tax (EBT)
1 |
-58.4
|
307.4
|
-76.76
|
-68.18
|
-75.48
|
-59.98
|
-66.68
|
-72.06
|
-61.87
|
-63.04
|
-58.65
|
-57.69
|
-55.38
|
-36.51
|
-51.29
|
Net income
1 |
-58.4
|
294
|
-76.72
|
-68.18
|
-75.48
|
-59.94
|
-66.68
|
-72.06
|
-61.87
|
-62.89
|
-58.07
|
-57.22
|
-55.21
|
-38.69
|
-51.29
|
Net margin
|
-189.79%
|
73.75%
|
-345.32%
|
-208.82%
|
-284.72%
|
-191.21%
|
-348.4%
|
-360.72%
|
-213.97%
|
-283.12%
|
-246.82%
|
-227.16%
|
-205.72%
|
-90.67%
|
-239.81%
|
EPS
2 |
-1.370
|
6.670
|
-1.790
|
-1.580
|
-1.750
|
-1.380
|
-1.530
|
-1.660
|
-1.410
|
-1.430
|
-1.267
|
-1.236
|
-1.183
|
-0.8597
|
-1.120
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
3/1/22
|
5/4/22
|
8/3/22
|
11/3/22
|
2/28/23
|
5/3/23
|
8/2/23
|
11/8/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
296
|
476
|
457
|
365
|
275
|
151
|
175
|
37.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-119
|
-80.9
|
-
|
-238
|
-228
|
-152
|
-24.4
|
-1.1
|
ROE (net income / shareholders' equity)
|
-19.8%
|
-26.9%
|
22.4%
|
-43.8%
|
-63.7%
|
-35.8%
|
-0.17%
|
2.66%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
12.20
|
10.10
|
17.80
|
11.90
|
7.080
|
6.950
|
7.220
|
7.710
|
Cash Flow per Share
2 |
-
|
-1.450
|
4.980
|
-4.810
|
-4.990
|
-2.770
|
3.760
|
-
|
Capex
1 |
11.7
|
26.9
|
84.2
|
30.7
|
9.96
|
9.55
|
14.3
|
21.3
|
Capex / Sales
|
33.26%
|
17.38%
|
17.9%
|
27.26%
|
11.04%
|
7.11%
|
6.55%
|
7.78%
|
Announcement Date
|
2/26/20
|
3/1/21
|
3/1/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
16.19
USD Average target price
39.83
USD Spread / Average Target +146.04% Consensus |
1st Jan change
|
Capi.
|
---|
| -9.81% | 794M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|